DA
VIR icon

Duality Advisers’s Vir Biotechnology VIR Stock Holding History

Duality Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-101,479
Closed -$1.03M – 515
2024
Q1 		$1.03M Buy
101,479
+6,331
+7% +$64.5K 0.1% 318
2023
Q4 		$957K Sell
95,148
-28,723
-23% -$262K 0.1% 306
2023
Q3 		$1.16M Buy
123,871
+105,139
+561% +$1.5M 0.14% 256
2023
Q2 		$459K Sell
18,732
-30,298
-62% -$761K 0.06% 404
2023
Q1 		$1.14M Sell
49,030
-7,157
-13% -$183K 0.13% 278
2022
Q4 		$1.42M Sell
56,187
-36,525
-39% -$895K 0.16% 229
2022
Q3 		$1.79M Sell
92,712
-23,703
-20% -$603K 0.19% 207
2022
Q2 		$2.96M Buy
116,415
+58,520
+101% +$1.37M 0.29% 111
2022
Q1 		$1.49M Buy
+57,895
New +$1.72M 0.16% 231

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Duality Advisers's VIR Position: Q2 2024 in Review

Duality Advisers sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 101,479 shares — an estimated $1.03M sold.

Duality Advisers first reported a position in VIR in Q1 2022 and held it in 9 quarters. The position peaked at $2.96M in Q2 2022. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

  • Duality Advisers reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 101,479 Vir Biotechnology shares in Q2 2024, an estimated $1.03M.
  • Duality Advisers first reported a position in Vir Biotechnology in Q1 2022 and held it in 9 quarters.
  • Duality Advisers's Vir Biotechnology position peaked at $2.96M in Q2 2022.
  • 215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.